Document Type : Review Article

Authors

1 Professor, Department of Physiology, Arak University of Medical Sciences, Arak, Iran

2 Physiologist, Department of Physiology, Abadeh Branch, Islamic Azad University, Abadeh, Iran

3 M.Sc. of Physiology, Islamic Azad University of Arsanjan, Arsanjan, Iran

4 Associate Professor, Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, 5th floor, Shariati Hospital, North Kargar, Tehran

5 Department of Nursing, School of Nursing Hazrat Zahra (P.B.U.H) Abadeh, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Background: Using herbs for the treatment of diseases has a long history. Chelidonium majus from the family of Papaveraceae is one of the best-known and most widely used herbs used in traditional medicine. The aim of this study was to review its active components, as well as its therapeutic and toxic effects on body tissues.
Methods: This short overview was done by searching for relevant contents in many databases including: Magiran, Iran medex, IranDoc, SID, Medlib, Web of Science, Scopus, PubMed, Science Direct and Google Scholar. All articles that met the inclusion criteria were studied and evaluated.
Results: The various compounds available in the plant such as: alkaloids, flavonoids, and opioid derivatives, as well as its ability to produce nitric oxide(NO) and tumor necrosis factor(TNF) and its multiple capabilities in affecting the activities of various body tissues in hepatic, renal, neurological, reproductive and hormonal systems have made it a leading plant in the listofmedicinalherbs.The levels of the active compounds in the plants are influenced by location, altitude, ambient temperature and harvest time, a fact which partly justifies the controversial  reports on the effects of this extract on body tissues.
Conclusion: Because of the multiplicity and diversity of its active ingredients, Chelidonium majus has the potential to be used for the diagnosis, treatment and control of hard to treat diseases (HTDS). However, it is recommended to do more research on its mechanism and its possible adverse effects.

Keywords

  1.  Zarei A, Changizi-Ashtiyani S, Rezaei A, Abdolyousefi N, Ghasemi A. The experimental study of the effect of hydro alcoholic extracts of Chelidonium majus on liver function tests and renal in rats with hypercholesterolemia. JMP. 2013; 4(48):117-25.
  2.  Biswas SJ. Chelidonium majus L. A review on pharmacological activities and clinical effects. Global. J Res. Med. Plants &Indigen. Med. 2013; 2(4):238-45.
  3. Zare SF, Baradaran B, Orangi M, Zamani F. In vitro Cytotoxic Activity of Four Plants Used in Persian Traditional Medicine. Adv Pharm Bull. 2013; 3(2):453-5.
  4. Maji AK, PratimBanerji P. Chelidonium majus L. (Greater celandine) - A review on its phytochemical and therapeutic perspectives. International Journal of Herbal Medicine. 2015; 3(1):10-27.
  5. Gilca ML, Gaman E, Panait I, Stoian, AtanasiuV. Chelidonium majus-an intergrative review: Traditional knowledge versus modern findings. Forsch Komplementmed. 2010; 17(5): 241-8.
  6. Miraj S. Ethnobotanical study and pharmacological properties of Chelidonium majus. Der Pharma Chemica, 2016, 8(14):216-22
  7. Bogucka-Kocka A, Zalewski D. Qualitative and Quantitative Determination of Main Alkaloids of Chelidonium majus L. ActaChromatographica. Acta Chromatographica. 2017; 29(3), 385–97.. Khurtsidze M, Aleksidze N, Alexidze G. Isolation of new lectins from the greater celandine plant(Chelidonium majus L.), study of theirproperties and distribution within the plant. Bull Georg. Natl. Acad. Sci. 2013;. 7:80-86.
  8. Moro PA, Cassetti F, Giugliano G, Falce MT, Mazzanti G, Menniti-Ippolito F, Raschetti R, Santuccio C. Hepatitis from greater celandine ( Chelidonium majus L.): review of literature and report of a new case. J Ethnopharmacol. 2009; 124(2):328-32.
  9. Biswas SJ, Bhattacharjee N, Khuda-Bukhsh AR. Efficacy of a plant extract (Chelidonium majus L) in combating induced hepatocarcinogenesis in mice. Food Chem Toxicol. 2008; 46(5):1474-87.
  10. Pantano F, Mannocchi G, Marinelli E, Gentili S, Graziano S, Busardò FP, et al. Hepatotoxicity induced by greater celandine (Chelidonium majus L.): Eur Rev Med Pharmacol Sci. 2017; 21(1 Suppl):46-52.
  11. Rupasri Dutt-Roy, Kayalvizhi E, Manikandan B, And Chandrasekhar M. Hepatoprotective effect Of Chelidonium majus. L extract against antitubercular drugs induced hepatic damage in wistar rats. Int J Pharm Bio Sci. 2015; 6(2): 677- 81.
  12. Yılmaz BS,,Ozbek H, SaltanÇitoglu G, Ugras S, Bayram I, Erdogan E. Analgesic and hepatoprotective effects of Chelidonium majus. Ankara Ecz. Fak. Derg. 2007; 36(1): 9-20.
  13. Habermehl D, Kammerer B, Handrick R, Eldh T, Gruber C, Cordes N, et al. Proapoptotic activity of ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. BMC Cancer. 2006; 6(1):14.
  14. Teschke R, Frenzel C, Glass X, Schulze J, Eickhoff A. Greater celandine hepatotoxicity. Ann Hepatol 2012; 11(6):838-48.
  15. Koriem KM, Arbid MS, Asaad GF. Chelidonium majus leaves methanol extract and its chelidonine alkaloid ingredient reduces cadmium-induced nephrotoxicity in rats. Journal of Natural Medicine. 2013; 67(1):159-67.
  16. Zarei A, Changizi-Ashtiyani S, Rezaei A, Sheidaee H, Nabiyoni F. The effect of Chelidonium majus herb extract on the lipid profile and activity of pituitary-gonadal axis in hypercholesterolemic rats. ZJRMS. 2013; 16(10): 18-22.
  17. Aqababa H, Mirzaee H, Zarei A, Akbarpour B, Changizi Ashtiyani S. Investigating the Effect of Chelidonium majus Alcoholic Extract on Pituitary-Thyroid in Hypercholesterolemia Male Rats. cmja. 2014; 4 (1) :757-765.[in Persian].
  18. Ulianich L, Secondo A, De Micheli S, Treglia S, Pacifico F, Liguoro D, et al. TSH/ cAMP up-regulate sarco/endoplasmic reticulum Ca2+-ATPases expression and activity in PC Cl3 thyroid cells. Eur. J. Endocrinol. 2004; 150(6), 851-61.
  19. Zarei A, Changizi-Ashtiyani S, Rezaei A, Sheidaee H, Nabiyoni F. The Effect of Chelidonium majus extract on the lipid profile and activity of pituitary-gonadal axis in hypercholesterolemic Rats. ZJRMS. 2014:16(10): 18-22.
  20. Hall JE. Guyton and Hall textbook of medical physiology. 12th ed. Philadelphia: USA.W.B. Saunders, 2010:881-976.
  21. Changizi-Ashtiyani S, Alizadeh M, Najafi H, Babaei S, Khazaei M, Jafari M, Hossaini N, Avan A, Bastani B. Physalis alkekengi and Alhagi maurorum ameliorate the side effect of cisplatin-induced nephrotoxicity. Cancer Gene Ther. 2016; 23(7):235-40.
  22.  Hardeman E, Van Overbeke L, Ilegems S, Ferrante M. Acute hepatitis induced by greater celandine (Chelidonium majus). Acta Gastroenterol Belg. 2008;71(2):281-2.
  23. Mendoza J, Zamora R, Gallardo JC, Ceballos G, Aldana A, Espinosa M, et al. NF-kappaB does not influence the induction of apoptosis by Ukraine. Cancer Biol Ther 2006; 5(7):788-93.
  24. Mazzanti G, Sotto A Di, Franchitto A, Mammola CL, Mariani P, Mastrangelo S, et al.Chelidonium majus is nothepatotoxic in Wistar rats, in a 4 weeks feeding experiment. J. Ethnopharmacol. 2009; 126(3):518-24..
  25. Mirfard M, Johari H, Mokhtari M, Hematkhah V, Jamali H, Allahverdi Gh. The effect of hydro-alcoholic garlic extract on testis weight and spermatogenesis in mature male rats under chemotherapy with cyclophosphamide. J Fasa Univ Med Sci. 2011; 1(3): 123-30.
  26. Song JY, Yang HO, Shim JY, Ji-Yeon-Ahn, Han YS, Jung IS, et al. Radiation protective effect of an extract from Chelidonium majus. Int. JHematol. 2003; 78(3):226-32.
  27. Kleinrok Z, Jagiello-Wojtowicz E, Matuszek B, Chodkowska A. A basic central pharmacological properties of thiophosphoric acid alkaloid derivatives from Chelidonium majus L. Pol. J. Pharmacol. Pharm. 1992; 44(3): 227-39.
  28. Farhadi A, Gavadifar K, Farhadi A. Effects of Berberise Vulgaris fruit extract on blood cholesterol and triglyceride in hyperlipidemic patients. Koomesh.. 2008;. 9(3):211-30.
  29. Taheri S, Zarei A, Changizi-Ashtiyani S, Rezaei A, Zaheiri S. Evaluation of the effects of hydro alcoholic extract of Berberis vulgaris root on the activity of liver enzymes in male hypercholesterolemic rats. AJP. 2012; 2(3): 153-61.
  30. Xia X, Yan J, Shen Y, Tang K, Yin J, Zhang Y, et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One. 2011 3; 6:e16556.
  31. Kim DH-, Lee JH, Park S, Oh SS, Kim S, Kim DW, et al. 6-Acetonyl-5,6-dihydrosanguinarine (ADS) from Chelidonium majus L. triggers pro inflammatory cytokine production via ROS-JNK/ERK-NFκB signaling pathway. Food ChemToxicol. 2013; 58:273-9.
  32. Gupta SL, Palod J, Singh SK. Serum-biochemical profile and immunomodulatory effect of Aeglemarmelos,Chelidonium majus and Boerhaaviadiffusa homeopathic mother tincture supplementation in guinea fowl. Indian J Anim Res. 2016; 50 (4): 493-96.
  33. Yang G, Lee K, Lee MH, Kim SH, Ham IH, Choi HY. Inhibitory effects of Chelidonium majus extract on atopic dermatitis-like skin lesions in NC/Nga mice. J Ethnopharmacol. 2011; 138(2):398-403.
  34. Park JE, Cuong TD, Hung TM, Lee I, Na M, Kim JC, et al. Alkaloids from Chelidonium majus and their inhibitory effects on LPS-induced NO production in RAW264.7 cells. Bioorganic & Medicinal Chemistry Letters. 2011; 21(23): 6960-63.
  35. Lee YC, Kim SH, Roh SS, Choi HY, Seo YB. Suppressive effects of Chelidonium majus methanol extract in knee joint, regional lymph nodes, and spleen on collagen-induced arthritis in mice. J Ethnopharmacol. 2007; 112:40-48.
  36. Yilmaz BS, Ozbek H, Citoglu GS, Ugraş S, Bayram I, Erdogan E. Analgesic and hepatoprotective effects of Chelidonium majus L. J. Fac. Pharm, Ankara. 2007; 36(1):9-20.
  37. Kim DS, Kim SJ, Kim MC, Jeon YD, Um JY, Hong SH. The therapeutic effect of Chelidonic acid on ulcerative colitis. Biol Pharm Bull. 2012; 35(5):666-71.
  38. Mikołajczak PŁ, Kędzia B, Ożarowski M, Kujawski R, Bogacz A, Bartkowiak-Wieczorek J, et al. Evaluation of anti-inflammatory and analgesic activities of extracts from herb of Chelidonium majus L. Cent Eur J Immunol. 2015; 40(4):400-10.
  39. Cahlikova, L, Opletal, L, Kurfurst, M, Macakova, K., Kulhankova, A. Acetylcholinesterase and Butyrylcholinesterase Inhibitory Compounds from Chelidonium majus (Papaveraceae). Nat. Prod. Commun. 2010; 5(11): 1751-1754.
  40. Capistrano IR, Wouters A, Lardon F, Gravekamp C, Apers S, Pieters L. In vitro and in vivo investigations on the antitumour activity of Chelidonium majus. Phytomedicine. 2015: 15; 22(14):1279-87.
  41. Park SW, Kim SR, Kim Y, Lee JH, Woo HJ, Yoon YK, et al. Chelidonium majus L. extract induces apoptosis through caspase activity via MAPK-independent NF-κB signaling in human epidermoid carcinoma A431 cells. Oncol Rep. 2015; 33(1):419-24.
  42. ZareShahneh F, Baradaran B, Orangi M, Zamani F. In vitro Cytotoxic Activity of Four Plants Used in Persian Traditional Medicine. Adv Pharm Bull. 2013, 3(2):, 453-55
  43. Deljanin M, Nikolic M, Baskic D, Todorovic D, Djurdjevic P, Zaric M, et al. Chelidonium majus crude extract inhibits migration and induces cell cycle arrest and apoptosis in tumor cell lines.J Ethnopharmacol. 2016; 190(1):362-71.
  44. Havelek R, Seifrtova M, Kralovec K, Krocova E, Tejkalova V, Novotny I, et al. Comparative cytotoxicity of chelidonine and homochelidonine, the dimethoxy analogues isolated from Chelidonium majus L. (Papaveraceae), against human leukemic and lung carcinoma cells. Phytomedicine. 2016; 23(3):253-66.
  45. TomeckovaI V, TkacovaII V, UrbanI P, StupakI M. The cytotoxic effect of Chelidonium majus in vitro. EMHPJ. 2015; 8(2):1-5.
  46. Hadaruga DI, Hadaruga NG. Antioxidant activity of Chelidonium majus L. extracts from the Banat county. J Agroaliment Proc Technol. 2009; 15(3):396-402.
  47. Papuc C, Crivineanu M, Nicorescu V, Predescu C, Rusu E. Scavenging activity of reactive oxygen species by polyphenols extracted from different vegetal parts of celandine (Chelidonium majus). Chemiluminescence Screening. Revista de Chimie. 2012; 63(2):193-197.
  48. Heo JI, Kim JH, Lee JM, Lim SS, Kim SC, Park JB, et al. Antioxidant activity and its mechanism of Chelidonium majus extract. KJMCS. 2013; 21(2):136-41.
  49. Jakovljevic ZD, Stankovic SM, Topuzovic DM. Seasonal variability of Chelidonium majus L. secondary metabolites content and antioxidant activity. Excli J. 2013; 12(1):260-8.
  50. Kocak C, Kocak FE, Akcilar R, Akcilar A, Savran B, Zeren S, et al. Ukrain (NSC 631570) ameliorates intestinal ischemia-reperfusion-induced acute lung injury by reducing oxidative stress. Bosn J Basic Med Sci. 2016; 16(1):75-81.
  51. Yao JY, Zhou ZM, Pan XY, Hao GJ, Li XL, Xu Y, et al. In vivo anthelmintic activity of chelidonine from Chelidonium majus L. against Dactylogyrusintermedius in Carassiusauratus. Parasitol Res. 2011; 109(5):1465-9.
  52. Monavari SH, Shahrabadi MS, Keyvani H, Bokharaei- Salim F. Evaluation of in vitro antiviral activity of Chelidonium majus L. against herpes simplex virus type-1. AJMR. 2012; 6(20):4360-64.
  53. Meng F, Zuo G, Hao X, Wang G, Xiao H, Zhang J, et al. Antifungal activity of the benzophenanthridine alkaloids from Chelidonium majus Linn against resistant clinical yeast isolates. J Ethnopharmacol. 2009; 125(3):494-96.
  54. Miao F, Yang XJ, Zhou L, Hu HJ, Zheng F, Ding XD, et al. Structural modification of sanguinarine and chelerythrine and their antibacterial activity. Natural Product Research. 2011; 25(9):863-75.
  55. Gohil KJ, Patel JA. Herb-drug interactions: A review and study based on assessment of clinical case reports in literature. Indian J Pharmacol. 2007; 39(3):129-39.